Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
about
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study.Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patientsOxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancerOral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsPhase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.The efficacy of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil and leucovorin in advanced colorectal cancer (preliminary data).Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapyIrinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in miceLongitudinal assessment of oxaliplatin-induced neuropathy.Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.Oxaliplatin-associated neuropathy: a review.Proposal for novel histological findings of colorectal liver metastases with preoperative chemotherapy.Clinicopathological observation of primary lung enteric adenocarcinoma and its response to chemotherapy: A case report and review of the literature.A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies.Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderlyHypersensitivity reactions related to oxaliplatin (OHP).A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.Capecitabine in the treatment of advanced gastric cancer.Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer.Phase II study of oxaliplatin, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as second line therapy.Oxaliplatin/5-FU without leucovorin chemotherapy in metastatic colorectal cancer.Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients.XELOX in colorectal cancer: a convenient option for the future?Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma: an asian experience.Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin.A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.Second-line therapy for advanced colorectal cancer.Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens.The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review.
P2860
Q24792125-B4B7F798-20E3-4CA2-A895-ECF3BD428D63Q28346039-50740FDB-5503-4F3B-A572-3C24F88CB8E6Q28364999-DD26BAB0-E107-44B4-9456-D080648FDF63Q30913489-72B5C532-EB19-45B7-96C5-80147B907A4EQ33361500-FAD54770-524A-4ED3-8620-13E920CA21A0Q33389163-CD4445E7-E5AB-4BB7-8921-133A28D59176Q33558347-2156707E-CFD1-4893-B118-9915DD4C2EF3Q34504536-F99151FF-18CF-4F46-BA41-0E55F6B5EC55Q35019148-9A66D9A1-8DD8-425F-BB13-F83328A6FB32Q35210263-E9D5ECB6-9A4E-44EB-9151-5929F12B720DQ35906972-F61AE8C3-5039-4D01-884D-755D129FA79DQ35980222-D7488CB4-D884-4316-8913-DB238E3592AFQ36402623-9E32BE96-C12C-4F38-9B97-246B70CC12FBQ36502148-2C33B9CF-4085-404D-A225-313E3AD05594Q36608816-DEDC89EE-52AF-4551-AE90-E99751E22E72Q36614800-67228D38-5855-4ED7-BFC4-D8C188C44164Q36624049-A2B63FE8-3C47-4C69-AF73-7D2861EF1557Q36634272-8FF7B4FE-D408-4B84-8DF5-B5E2676347EEQ36671275-17DC9032-80FD-4B54-B57B-610A934BBFB2Q36671350-76FD41CC-56BC-455B-AD2F-2E799676F8F1Q36973778-E7A4B800-8807-4B95-9C3B-8D83E02ED0CFQ37136996-87EA7BEE-AB66-4C1D-B2EC-963F068FF7C8Q37220492-FAB1B795-E8A4-43C0-BBE9-D706491EEFBDQ37341645-C71F6D7F-5DE0-444E-A04F-6E088A41211AQ37449141-11183143-4E38-40BA-A17B-960C6944A56FQ37595260-E4A61B04-102A-49A3-8D0D-70BF5E0A3137Q37839084-3D3003D5-DD07-4C25-89F7-629E9EFBDDE0Q38799295-B4A63DE9-F072-4985-B2CD-4432A84DDB28Q39081778-8AD05EA8-FBE0-4270-9C17-E1AA0F6CD0FFQ39579889-42229926-B058-4979-8F0C-8A89C8BC7FE3Q42536866-C4142283-08B9-4363-9150-3C25B398F28CQ42770955-C97123FB-838B-4C64-8E04-1DC19590A694Q43191517-16977BAA-8EAD-4E74-BA3C-8C6D98CC71DAQ43278321-3F8A0F63-D379-4F2E-8BFE-7477E0B71390Q44181002-BAD300FA-487A-4FE2-965D-B93AB0107EB7Q44610555-860B4594-69C7-4250-A99A-68A988F9D8ACQ44938504-CDC6D8A8-3189-48BD-8DDB-3F76C0B0C6F3Q52591422-B2BCCC08-FB87-4660-B2AA-F7EAE258DB71
P2860
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Multicenter phase II study of ...... orin and fluorouracil regimen.
@ast
Multicenter phase II study of ...... orin and fluorouracil regimen.
@en
Multicenter phase II study of ...... orin and fluorouracil regimen.
@nl
type
label
Multicenter phase II study of ...... orin and fluorouracil regimen.
@ast
Multicenter phase II study of ...... orin and fluorouracil regimen.
@en
Multicenter phase II study of ...... orin and fluorouracil regimen.
@nl
prefLabel
Multicenter phase II study of ...... orin and fluorouracil regimen.
@ast
Multicenter phase II study of ...... orin and fluorouracil regimen.
@en
Multicenter phase II study of ...... orin and fluorouracil regimen.
@nl
P2093
P1476
Multicenter phase II study of ...... orin and fluorouracil regimen.
@en
P2093
A de Gramont
E François
F Desseigne
G Dupont-André
K Beerblock
M A Bensmaine
P304
P356
10.1200/JCO.1999.17.11.3560
P407
P577
1999-11-01T00:00:00Z